Topical phenylbutyrate antagonizes NF-κB signaling and resolves corneal inflammation
AffiliationKen Coit College of Pharmacy, The University of Arizona
MetadataShow full item record
CitationKoganti, R., Yadavalli, T., Sutar, Y., Mallick, S., Date, A., & Shukla, D. (2022). Topical phenylbutyrate antagonizes NF-κB signaling and resolves corneal inflammation. Iscience, 25(12), 105682.
Rights© 2022 The Authors. This is an open access article under the CC BY-NC-ND license.
Collection InformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at firstname.lastname@example.org.
AbstractChronic inflammation of the immune privileged cornea originating from viral or nonviral conditions results in significant vision loss. Topical corticosteroids are the common treatments for corneal inflammation, but the drugs cause serious and potentially blinding side effects in the long term. Therefore, new standalone and/or synergistic anti-inflammatory therapies with lower side effects are desperately needed. Here, we show that the aromatic fatty acid phenylbutyrate (PBA) acts as a potent inhibitor of inflammation in preclinical ocular-inflammation models. PBA prevents the transcription as well as translation of pro-inflammatory cytokines by LPS and poly(I:C) via persistent inhibition of NF-κB signaling. PBA quickens the resolution of ocular inflammation in mice by decreasing corneal thickness and immune cell infiltration. More importantly, PBA can synergize with the dexamethasone to antagonize NF-κB signaling at lower drug concentrations. Our results demonstrate that PBA therapy exerts previously unreported anti-inflammatory effects in the eye and facilitates corneal healing during persistent inflammation. © 2022 The Authors
NoteOpen access journal
VersionFinal published version
Except where otherwise noted, this item's license is described as © 2022 The Authors. This is an open access article under the CC BY-NC-ND license.